| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $476.6M | +43.4% |
| SG&A Expense | $92.9M | +53.1% |
| Operating Income | -$569.5M | -21.7% |
| Net Income | -$463.9M | -15.3% |
| EPS (Basic) | -$3.80 | +8.2% |
| EPS (Diluted) | -$3.80 | +8.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $387.9M | -2.4% |
| Short-term Investments | $1.36B | +99.1% |
| Current Assets | $1.79B | +63.1% |
| Total Assets | $3.51B | +149.4% |
| Current Liabilities | $140.2M | -3.5% |
| Total Liabilities | $205.5M | +22.7% |
| Stockholders' Equity | $3.31B | +166.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$452.6M | -52.5% |
| Capital Expenditures | $22.4M | +39.6% |
| Investing Cash Flow | -$2.01B | -159.4% |
| Financing Cash Flow | $2.45B | +282.7% |
| Free Cash Flow | -$475.1M | -51.8% |